Loading
A phase 2 trial of ABP1011T in small-cell lung cancer, run by Shanghai AB PharmaTech Ltd., now recruiting.
A Study Evaluating the Efficacy and Safety of ABP1011T Tablets in Patients With Advanced Solid Tumors is a phase 2 interventional study registered as NCT07321574 by Shanghai AB PharmaTech Ltd., with 110 participants planned, started 2025-12-30 and due to reach its primary completion in 2028-11-28. Interventions recorded: ABP1011T.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Small-cell lung cancer and the tag pipeline.
Shares Small-cell lung cancer and the tag pipeline.
Shares Small-cell lung cancer and the tag pipeline.
Shares Small-cell lung cancer and the tag pipeline.
Shares Small-cell lung cancer and the tag pipeline.
Shares Small-cell lung cancer and the tag pipeline.
Shares Small-cell lung cancer and the tag pipeline.
Shares Small-cell lung cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/